Ionis Pharmaceuticals (NASDAQ: IONS) CEO reports RSU grants and tax sale
Rhea-AI Filing Summary
Ionis Pharmaceuticals Chief Executive Officer and director Brett P. Monia reported multiple equity award transactions and a related share sale. On January 15, 2026, 89,145 shares of common stock were acquired at $0.0 per share through the vesting and release of previously granted restricted stock units, increasing his directly held common stock to 268,717 shares. On the same day, he received 113,880 Performance Restricted Stock Units (PRSUs), representing the maximum earnable amount based on a three-year performance period, and 42,705 additional restricted stock units under the company’s equity incentive plan.
On January 16, 2026, Monia sold 44,034 common shares at a weighted average price of $74.82 per share in an automatic sale to cover required tax withholding obligations tied to the RSU vesting. Following these transactions, he directly beneficially owned 224,683 shares of common stock, alongside substantial outstanding PRSU and RSU awards that may convert into shares or cash in the future based on vesting and performance conditions.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 44,034 | $74.82 | $3.29M |
| Grant/Award | Performance Restricted Stock Units | 113,880 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 89,145 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 42,705 | $0.00 | -- |
| Exercise | Common Stock | 89,145 | $0.00 | -- |
Footnotes (1)
- Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards. The sale was made pursuant to an automatic sale to cover the required tax withholding obligations pursuant to the 2011 Equity Incentive Plan Restricted Stock Unit Agreement and Grant Notice. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.57 to $75.07 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. Grant to reporting person of Performance Restricted Stock Units (PRSUs) under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan. The PRSUs may vest at the end of the three-year performance period following the date of grant based on the Issuer's relative total shareholder return as compared to a peer group of companies. The number of PRSUs reported represents the maximum that may be earned, which is 200% of the target number. No number of PRSUs is guaranteed to vest and the actual number of PRSUs that will vest at the end of the performance period may be anywhere from zero to the amount stated. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value. Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company. Grant to reporting person of Restricted Stock Units under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
FAQ
What insider transactions did Ionis Pharmaceuticals (IONS) CEO Brett Monia report?
Brett P. Monia reported the vesting of 89,145 restricted stock units into common stock, a grant of 113,880 Performance Restricted Stock Units and 42,705 additional restricted stock units on January 15, 2026, and the sale of 44,034 common shares on January 16, 2026 to cover tax withholding.
What Performance Restricted Stock Units did the Ionis (IONS) CEO receive?
On January 15, 2026, Brett P. Monia received a grant of 113,880 Performance Restricted Stock Units (PRSUs) under the Amended and Restated 2011 Equity Incentive Plan. This number represents the maximum that may be earned based on a three-year performance period tied to Ionis’s relative total shareholder return.
What are the vesting conditions for the Ionis (IONS) CEO’s PRSUs and RSUs?
The PRSUs may vest at the end of a three-year performance period based on Ionis’s relative total shareholder return versus a peer group, with potential payout from zero up to the 113,880-unit maximum. The restricted stock units generally vest in four equal annual installments, and each unit represents a contingent right to receive one share of Ionis common stock or its cash equivalent upon vesting.